Home/Pipeline/Adjuvanted Cell-Based COVID-19 Vaccine

Adjuvanted Cell-Based COVID-19 Vaccine

COVID-19

MarketedCommercial (region-dependent)

Key Facts

Indication

COVID-19

Phase

Marketed

Status

Commercial (region-dependent)

Company

CSL Seqirus

About CSL Seqirus

CSL Seqirus is a mission-driven global leader in influenza vaccines, leveraging its position within the CSL Limited ecosystem to advance public health. Its strategy is built on a diversified technology platform, a broad product portfolio, and a robust global manufacturing footprint. The company plays a pivotal role in seasonal flu prevention and is a key partner to governments worldwide for pandemic response, underpinned by continuous R&D and strategic in-licensing.

View full company profile

Therapeutic Areas

Infectious Disease Pandemic Preparedness

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
Sequential Dialysis Technique	Halberd	Discovery	Conceptual / Dormant
Amubarvimab + Romlusevimab (BRII-196/BRII-198)	Brii Biosciences	Approved	Commercial (China)
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active